No Data
Express News | Zhejiang Garden Biopharmaceutical: plans to establish a subsidiary in Macau.
Zhejiang Garden Biopharmaceutical (300401): A Global leader in integrated VD3, advancing towards a comprehensive big health nutrition enterprise.
Abstract: Zhejiang Garden Biopharmaceutical, as a leading enterprise in the Global Vitamins D3 Industry Chain, relies on its independent NF grade cholesterol production technology and 25-hydroxy vitamin D3 synthesis process, mastering the process from lanolin cholesterol to 25-hydroxy VD3.
Zhejiang garden biopharmaceutical (300401): VD3 leader is expected to benefit from the price increase of VD3. The raised investment project will add capacity for VA/VE/VB6.
The company's main business includes upstream and downstream series products of vitamins D3, as well as the research, production, and sales of formulations in the field of chronic diseases such as cardiovascular and neurological systems. 1) The main products in the vitamin sector include lanolin cholesterol, vitamin D3, and 25.
Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.
Gelonghui, November 22nd丨 Zhejiang Garden Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary Zhejiang Garden Pharmaceutical Co., Ltd. (hereinafter referred to as "Garden Pharmaceutical") recently received the "Drug Registration Certificate" for Alendronate Sodium Tablets approved and issued by the National Medical Products Administration. Alendronate Sodium Tablets are primarily used to treat osteoporosis in postmenopausal women and male osteoporosis to increase bone mass. Alendronate Sodium Tablets are classified as Type B in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)".
Express News | Zhejiang garden biopharmaceutical: Subsidiary obtained the registration certificate for alendronate sodium tablets pharmaceutical.
Zhejiang garden biopharmaceutical (300401.SZ): The company's convertible bonds vitamin A project has started production.
On November 11, Zhejiang Garden Biopharmaceutical (300401.SZ) stated on the investor interaction platform that the company's convertible bonds for the vitamin A project have already begun production.
No Data
